Table 1.
Patient Descriptive Statistics According to Receipt of Post-Operative Radiotherapy (PORT)
| PORT | ||||
|---|---|---|---|---|
| Characteristic | Total (n=2115) | No (N=1197) | Yes (N=918) | P value* |
| Facility Type | <0.001† | |||
| Community Cancer Program/Other | 170 (8.0%) | 81 (6.77%) | 89 (9.69%) | |
| Comprehensive Community Cancer Program | 1098 (51.9%) | 594 (49.62%) | 504 (54.9%) | |
| Academic/Research Program (Includes NCI) | 847 (40%) | 522 (43.61%) | 325 (35.4%) | |
| Sex | 0.340 | |||
| Male | 991 (46.9%) | 550 (45.95%) | 441 (48.04%) | |
| Female | 1124 (53.1%) | 647 (54.05%) | 477 (51.96%) | |
| Age | <0.001† | |||
| Median | 64 | 65 | 62 | |
| Range | 27–89 | 27–89 | 30–84 | |
| Race | 0.402 | |||
| White | 1831 (87 5%) | 1026 (86 95%) | 805 (88 17%) | |
| Other | 262 (12 5%) | 154 (13 05%) | 108 (11 83%) | |
| Insurance | <0 001† | |||
| Not Insured | 41 (2 0%) | 23 (1 95%) | 18 (1 99%) | |
| Private Insurance | 963 (46 3%) | 492 (41 77%) | 471 (52 1%) | |
| Govt Insurance | 1078 (51 8%) | 663 (56 28%) | 415 (45 91%) | |
| Income | 0 038† | |||
| < $30 000 | 252 (12 5%) | 151 (13 36%) | 101 (11 43%) | |
| $30 000 $34 999 | 387 (19 2%) | 195 (17 26%) | 192 (21 72%) | |
| $35 000 $45 999 | 539 (26 8%) | 297 (26 28%) | 242 (27 38%) | |
| $46 000 + | 836 (41 5%) | 487 (43 1%) | 349 (39 48%) | |
| Urban/Rural | 0 292 | |||
| Metro Area | 1655 (82 9%) | 937 (83 66%) | 718 (81 87%) | |
| Urban/Rural | 342 (17 1%) | 183 (16 34%) | 159 (18 13%) | |
| Charlson Deyo Score | 0 001† | |||
| 0 | 1292 (61 1%) | 692 (57 81%) | 600 (65 36%) | |
| 1 | 638 (30 2%) | 396 (33 08%) | 242 (26 36%) | |
| 2+ | 185 (8 7%) | 109 (9 11%) | 76 (8 28%) | |
| Year of Diagnosis | 0 079 | |||
| 2004 | 673 (31 8%) | 357 (29 82%) | 316 (34 42%) | |
| 2005 | 694 (32 8%) | 405 (33 83%) | 289 (31 48%) | |
| 2006 | 748 (35 4%) | 435 (36 34%) | 313 (34 1%) | |
| Histology | 0 761 | |||
| Large cell carcinomas | 131 (6 2%) | 76 (6 35%) | 55 (5 99%) | |
| Squamous cell carcinomas | 502 (23 7%) | 288 (24 06%) | 214 (23 31%) | |
| Adenocarcinomas | 1407 (66 5%) | 787 (65 75%) | 620 (67 54%) | |
| Adenosquamous carcinomas | 75 (3 5%) | 46 (3 84%) | 29 (3 16%) | |
| Grade | 0 085 | |||
| 1 | 107 (5 1%) | 66 (5 51%) | 41 (4 47%) | |
| 2 | 877 (41 5%) | 520 (43 44%) | 357 (38 89%) | |
| 3 | 936 (44 3%) | 509 (42 52%) | 427 (46 51%) | |
| 4 | 81 (3 8%) | 46 (3 84%) | 35 (3 81%) | |
| Unknown | 114 (5 4%) | 56 (4 68%) | 58 (6 32%) | |
| AJCC Pathologic T stage | 0 092 | |||
| T0/1 | 712 (33 8%) | 386 (32 36%) | 326 (35 67%) | |
| T2 | 1147 (54 4%) | 671 (56 24%) | 476 (52 08%) | |
| T3 | 114 (5 4%) | 69 (5 78%) | 45 (4 92%) | |
| T4 | 134 (6 4%) | 67 (5 62%) | 67 (7 33%) | |
| Regional Nodes Positive | 0 314 | |||
| 1 2 | 987 (49 5%) | 568 (50 49%) | 419 (48 22%) | |
| > 3 | 1007 (50 5%) | 557 (49 51%) | 450 (51 78%) | |
| Median | 3 | 2 | 3 | |
| Range | 1 34 | 1 34 | 1 20 | |
| Regional Nodes Examined | <0 001† | |||
| 1 3 | 221 (11 7%) | 93 (8 74%) | 128 (15 53%) | |
| 4 6 | 344 (18 2%) | 194 (18 23%) | 150 (18 2%) | |
| 7 9 | 351 (18 6%) | 217 (20 39%) | 134 (16 26%) | |
| >9 | 972 (51 5%) | 560 (52 63%) | 412 (50%) | |
| Median | 10 | 10 | 9 5 | |
| Range | 1 68 | 1 68 | 1 55 | |
Abbreviations: NCI: National Cancer Institute; AJCC: American Joint Committee on Cancer
*
ANOVA for numerical covariates and chi-square test for categorical covariates.
†
Significant